This biochemical, genetic, and pharmacological evidence suggests that the inhibition of PTP1B may be an effective strategy in the treatment of metabolic syndromes, such as type 2 diabetes and obesity and cancer. This evidence concerns the gene PTPN1 and obesity due to melanocortin 4 receptor deficiency.